uniQure (NASDAQ:QURE) Shares Down 2.4% - What's Next?

uniQure N.V. (NASDAQ:QURE - Get Free Report) fell 2.4% during mid-day trading on Friday . The company traded as low as $14.86 and last traded at $14.83. 152,461 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 1,431,538 shares. The stock had previously closed at $15.20.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on QURE. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Chardan Capital restated a "buy" rating and issued a $38.00 price objective on shares of uniQure in a report on Friday, May 30th. Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Guggenheim restated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. Finally, HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Thursday, May 29th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $37.82.

uniQure Stock Performance

The firm has a fifty day simple moving average of $14.72 and a 200 day simple moving average of $13.82. The company has a market cap of $823.78 million, a price-to-earnings ratio of -3.43 and a beta of 0.08. The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.25. The business had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. On average, sell-side analysts expect that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Robert Gut sold 3,336 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $48,205.20. Following the sale, the director owned 56,879 shares in the company, valued at approximately $821,901.55. This trade represents a 5.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Madhavan Balachandran sold 2,112 shares of the firm's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the sale, the director owned 37,697 shares in the company, valued at approximately $544,721.65. The trade was a 5.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock valued at $322,426 in the last 90 days. 4.79% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. Avoro Capital Advisors LLC bought a new position in shares of uniQure during the 4th quarter worth about $38,410,000. Vestal Point Capital LP lifted its holdings in shares of uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after acquiring an additional 1,767,572 shares during the period. RTW Investments LP lifted its holdings in shares of uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock worth $15,958,000 after acquiring an additional 893,625 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock worth $31,282,000 after acquiring an additional 794,459 shares during the period. Finally, Boxer Capital Management LLC bought a new position in shares of uniQure during the 4th quarter worth about $13,245,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.